GOSS Gains Buzz on Reddit as PAH Drug Nears NDA Submission

Gossamer Bio (GOSS) received a positive regulatory update in late July 2026, with a planned NDA submission for seralutinib in PAH expected in September.
A detailed Reddit post on r/pennystocks drove the ticker's discussion, generating 28 comments and 11 upvotes, with a bullish sentiment of 0.16.
Analysts remain bullish on GOSS, with price targets suggesting significant upside from current levels, despite high short interest and the company's pre-commercial status.

On July 31, 2026,

$GOSS emerged as a standout ticker in retail investor discussions, ranking 16th overall with 6 posts and 54 comments. The conversation centered on a comprehensive r/pennystocks post that detailed the company's progress with its lead drug candidate, seralutinib, and the anticipated regulatory catalyst.

Why GOSS Stood Out Today

The Reddit post titled "IF YOU LOVE DRUGS, HERE'S A GOOD PILL FOR YOU (AUGUST) TICKER (GOSS)" compiled a detailed breakdown of

$GOSS's pipeline, regulatory status, and analyst outlook. The post highlighted that the company had completed a positive Pre-NDA meeting with the FDA for seralutinib in pulmonary arterial hypertension (PAH), paving the way for a New Drug Application (NDA) submission in September 2026. The discussion also noted that Gossamer Bio recently reacquired worldwide rights to the drug from Chiesi, strengthening its commercial prospects.

GOSS

Company Context

$GOSS is a clinical-stage biopharmaceutical company based in San Diego, California. Its lead asset, seralutinib (formerly GB002), is an inhaled small-molecule inhibitor targeting PDGFR, CSF1R, and c-KIT pathways. The drug is being developed for PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has completed the Phase 3 PROSERA trial and is now preparing for regulatory submission. Despite being pre-commercial with ongoing losses and a history of capital raises, the recent positive regulatory update has reignited investor interest.

What’s Driving the Discussion

The primary catalyst driving the Reddit conversation is the upcoming NDA submission for seralutinib, which could position

$GOSS as a potential player in the PAH treatment market. The r/pennystocks post also pointed to bullish analyst price targets, suggesting significant upside from the stock's current level. The post’s author noted that high short interest could add volatility, but the regulatory milestone remains the key narrative. With a sentiment score of 0.16 and a sharp rise in engagement (rank delta of +3424),

$GOSS clearly captured the attention of retail traders looking for a high-risk, high-reward biotech play.

Subscribe to Tendie.bot for more market recaps.